May 2026 Research Update

This month, studies of newborn screening focused on reducing false-positive results without missing babies with classical CAH. Across two programs, adding a rapid second-tier bloodspot test after the first screening step made the screening process much more specific, meaning fewer families were called back unnecessarily while classical CAH cases were still identified. These results strengthen the idea that improving the second step of screening can make the overall experience safer and less stressful for families. [1] [2]

In Sweden, adding a second-tier LC-MS/MS test that included 21-deoxycortisol and a hormone ratio with gestational-age adjusted cutoffs reduced false positives by 88% and improved the positive predictive value, especially in full-term infants. In a 3-year follow-up of the updated approach, the program reported no missed classic CAH cases identified during follow-up, while referrals dropped (for example, from 88 to 31). This suggests that better second-tier testing can substantially reduce unnecessary urgent evaluations after screening, while keeping a safety net for the more severe forms. [1]

In New Zealand, researchers evaluated 21-deoxycortisone as a second-tier bloodspot marker using stored screening samples and found very high accuracy in this set of specimens (98.1% sensitivity and 100% specificity). The study also reported that 21-deoxycortisone performed better than a related marker (21-deoxycortisol) in their comparison. Because this was a retrospective evaluation using long-stored samples, the authors noted that prospective validation is still needed before it can be considered proven in real-time screening. [2]

For families, these studies add encouraging evidence that newborn screening can be made more accurate, which could mean fewer false alarms and fewer urgent follow-up visits that turn out not to be CAH. The Swedish program evaluation is closest to real-world practice because it looked at program outcomes over time, while the New Zealand work is earlier-stage but points to a promising additional marker that could be tested in future programs. What remains uncertain is how these approaches perform across different countries, lab setups, and in milder CAH forms, since follow-up time and stored-sample testing both have limits. [1] [2]

This month, adult CAH studies linked day-to-day hormone control with longer-term cardiometabolic health, such as weight distribution, insulin resistance, and blood pressure. One study tracking people who switched steroid schedules reported stable hormone control with less overall steroid exposure and some metabolic improvements over time. Another study, looking across adults in routine care, found that body fat patterns and insulin resistance lined up differently with biochemical control in men versus women. [3] [4]

In a prospective observational cohort of 62 adults with classic CAH due to 21-hydroxylase deficiency, switching from conventional glucocorticoids to modified-release hydrocortisone (MR-HC; Efmody) was accompanied by maintained biochemical control and a lower median daily hydrocortisone-equivalent dose (30 mg to 25 mg). The study also reported improved insulin sensitivity (HOMA-IR decreased from 2.15 to 1.67) and about a 5 mmHg reduction in daytime blood pressure, alongside mixed menstrual changes (some improved, some worsened). It also reported an adrenal crisis rate of 5.0 per 100 patient-years during follow-up, giving context for ongoing risk even with a modified schedule. [3]

In a retrospective Italian study of 123 adults with classic CAH, men had higher measures of adiposity and visceral fat than women, and a larger share were categorized as uncontrolled. Measures tied to visceral adiposity and glucose metabolism were more strongly linked to poorer biochemical control in men, while 17-hydroxyprogesterone levels helped predict control in both sexes. This adds a clearer picture that metabolic health and hormone control travel together for many adults with CAH, and that the pattern may not be the same for everyone. [4]

For adults living with CAH, these studies add detail to a question many people already think about: how steroid treatment patterns and hormone control connect to blood pressure, insulin resistance, and body weight. The MR-HC follow-up offers moderate-strength, real-world evidence that a different hydrocortisone release pattern can coincide with lower total steroid exposure and some measurable metabolic changes, but it does not prove cause-and-effect because it was not a randomized comparison. The multicenter Italian analysis does not test a treatment, but it helps clarify that visceral fat and insulin resistance may be warning signs for harder-to-control hormones, particularly in men, while some hormone markers matter across sexes. What remains uncertain is which changes are driven by medication schedules versus other factors like lifestyle, stress, or long-term disease biology. [3] [4]

This month, two studies focused on practical, everyday issues for families: how stress may relate to crisis-like episodes, and how clinicians estimate growth outcomes in childhood CAH. The stress survey highlights that many caregivers connect emotional stress with symptoms they interpret as adrenal crisis and often respond by increasing steroids at home, sometimes still needing emergency care. The growth study suggests that using an automated tool to read bone age can make predicted adult height closer to what later happened in girls, which could reduce confusion when families discuss growth expectations. [5] [6]

In a US parent-reported cross-sectional study (115 parents representing 118 children), 24.3% of children were reported to have had suspected psycho-emotional adrenal crisis events at some point, and 11.3% had a suspected event in the prior year. About half of parents reported proactively increasing glucocorticoid doses during psycho-emotional stress, and roughly one-third of suspected events required emergency medical care. Because these were caregiver-reported suspected events rather than medically confirmed crises, the study mainly shows how common and disruptive these episodes are perceived to be in real life. [5]

In children with classic salt-wasting CAH, an observational study compared predicted adult height based on clinician-read bone age versus automated BoneXpert bone age, then checked which prediction was closer to near-final height. The automated approach produced predictions closer to near-final height in girls, while the difference was not significant in boys. The study also reported that predicted and near-final heights were lower than target height in both sexes, helping set realistic expectations about growth even when using improved prediction tools. [6]

For families, the stress survey matters now because it documents that many caregivers already experience and manage stress-related symptom episodes, even though it cannot confirm how often these were true adrenal crises. It helps clarify that emotional stress is commonly perceived as a trigger and that home management is frequent, but it also shows that emergency care is sometimes still needed in these situations. The growth study matters more as a communication and monitoring tool: it suggests that automated bone-age reading may improve height prediction for girls, which could make growth discussions feel more consistent over time, while predictions are still imperfect and can differ by sex. [5] [6]

This month added several reminders that CAH is not one single condition and that the diagnostic pathway can be complicated, especially for rarer forms. Across cohort reports, people with 17alpha-hydroxylase deficiency and lipoid CAH had long-term issues involving blood pressure, puberty, growth, and bone health, with wide variation between individuals. Across case reports, clinicians initially suspected a different diagnosis in both directions: CAH was missed in an adult woman, and CAH was suspected in an infant whose crisis turned out to be a different condition. [7] [8] [9] [10] [11]

In a Korean multicenter cohort of 17 patients with genetically confirmed 17alpha-hydroxylase/17,20-lyase deficiency, hypertension and low potassium were common, and diagnosis often happened in adolescence (median 16.4 years). Over follow-up, many patients achieved normal blood pressure with glucocorticoids and/or antihypertensives, and low bone mineral density improved with sex hormone replacement. This reinforces that some CAH forms may not be recognized until puberty-related concerns appear, and that long-term monitoring often extends beyond adrenal hormones alone. [7]

In the Korean OUTSPREAD cohort of 31 patients with lipoid CAH, classic disease usually presented in infancy with salt-wasting and hyperpigmentation, and most had a female phenotype regardless of karyotype. Puberty and growth outcomes varied, with some spontaneous puberty milestones reported in 46,XX individuals and adult height reported in a subset. The report also noted that hydrocortisone dosing tended to be lower at last follow-up than at diagnosis, describing how treatment needs can change over time in routine care. [8]

The case reports collectively show how CAH and non-CAH conditions can be confused when the main problem is salt-wasting or atypical reproductive development. One neonate had a life-threatening salt-wasting picture initially thought to be CAH but was diagnosed with transient secondary pseudohypoaldosteronism related to severe dehydration and kidney injury, with vesicoureteral reflux as an underlying urinary tract problem. Another report described a 33-year-old woman initially labeled with MRKH syndrome because of a small uterus, but genetic testing later showed simple virilizing CAH (CYP21A2 I172N), and after treatment she had menarche at age 33. [10] [9]

A small case series of three children with 17alpha-hydroxylase deficiency described hypertension and low potassium that improved after glucocorticoids and spironolactone, and it also reported a novel genetic variant. The authors highlighted an unusual growth pattern where height exceeded what bone age would predict, suggesting a possible clue when gene testing is not available. Because this is based on only three children, it mainly expands the range of reported presentations rather than defining a typical pattern. [11]

For patients and caregivers, these studies mainly add understanding rather than changing care right now. They help clarify that rarer CAH forms can show up later with puberty concerns or high blood pressure, and that long-term health issues can include bones and growth as well as adrenal hormones. The case reports underline that correct diagnosis can be difficult when symptoms overlap with other conditions, which is why genetic and endocrine testing sometimes becomes important to sort out the cause. What remains uncertain is how often these exact diagnostic mix-ups happen, since case reports highlight unusual situations rather than typical ones. [7] [8] [10] [9] [11]

This month included studies about how CAH care is delivered and supported, not just biology. A large clinician survey suggested that workforce training may be a bottleneck as more CAH is found through newborn screening. Separately, a small reproductive genetics report showed how some families use embryo testing and prenatal testing to reduce the chance of an affected child. A broad expert statement also placed CAH within a bigger endocrine picture where lipid (cholesterol) changes can contribute to long-term cardiometabolic risk. [12] [13] [14]

In Indonesia, a nationwide survey of 416 pediatric residents and pediatricians found similar overall CAH knowledge between the two groups, but only 15.1% felt sufficiently knowledgeable to manage CAH. Most respondents said they first encountered CAH later in residency, and many expressed a need for more training in anticipation of increased CAH detection through newborn screening. For families, this connects to access and consistency of care, since experience and training can shape how quickly CAH is recognized and how confidently it is managed. [12]

In a retrospective report involving three families with CYP21A2-related 21-hydroxylase deficiency, an integrated pathway combined genetic diagnosis, preimplantation genetic testing for monogenic disease (PGT-M), chromosome screening (PGT-A), and prenatal diagnosis. All couples obtained transferable embryos (normal or carrier), leading to two clinical pregnancies with one miscarriage, and prenatal testing matched the embryo testing results in the ongoing pregnancies that resulted in healthy births. Because the numbers were very small, this is best read as a real-world example of what is technically possible rather than a measure of typical success rates. [13]

A position statement on lipid disorders across endocrine diseases included CAH among conditions with distinct lipid patterns that can contribute to cardiometabolic risk and may be underrecognized. The paper did not present new CAH patient data, but it reinforces that cholesterol and related labs are part of the broader health picture in endocrine conditions. For patients, this is context for why research and care discussions often include metabolism and heart-health risk factors alongside hormone control. [14]

For patients, this set of papers mostly matters at the health-system and life-planning level rather than changing any specific treatment. The Indonesian survey suggests that, as screening expands, training and experience may influence how smoothly families move from a positive screen to specialized care. The reproductive genetics report may matter now for a small group of families already considering in vitro fertilization and genetic testing, but it is early evidence based on only three families. The lipid position statement does not add new CAH-specific results, but it supports ongoing attention in research to cardiometabolic health in CAH as part of whole-body, long-term wellbeing. [12] [13] [14]